Fresh analysis suggests that patients who stop using popular slimming jabs like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who end traditional diet and exercise programs.
Findings released in a major medical journal shows that while obese individuals can lose substantial amounts of their total mass while undergoing treatment, the mass comes back at an average rate of nearly a kilo each month once they quit.
"Individuals purchasing such drugs must be informed of the risk of quick weight regain when the therapy ends," stated lead investigator Dr. Susan Jebb.
That rate of recovery means a return to original weight within about a year and a half.
Weighing Treatments
The analysis, which examined 37 of trials involving over 9,000 of patients, contrasted the results of these new drugs with other pills.
The team point out that individuals who shed pounds through lifestyle changes alone generally have a slower creep back—approximately 0.1 kg a month—after stopping.
The Reason for the Rapid Regain
Nutrition scientists believe the mode of action of the injections explains the heightened weight return.
The injections mimic a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Sustained high doses of the hormone levels far above than the body's typical production might result in the system to produce less of its endogenous GLP-1, and may also diminish sensitivity to its effects," explained Dr. Adam Collins, a dietetics expert.
"Stopping of this hormone supplement leads to appetite is no longer kept in check, making overeating far more likely."
An Ongoing Issue?
The NHS advise the injections for people with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
A number of clinicians argue that, due to the likelihood of relapse, the therapy might need to be long-term.
This perspective is reinforced by drug manufacturers, who state that the findings "highlight the long-term character of excess weight," akin to managing diseases like hypertension.
User Testimonies
People who have come off the jabs describe a intense resurgence of cravings.
"It felt as if a trigger flipping and you become starving," said one woman.
This challenge is compounded if individuals have not developed permanent dietary or behavioural changes during treatment.
Growing Use
Survey data show that a significant number of adults in the UK have tried weight-loss jabs in the past year, with desire being substantial.
- Use is higher among females than men.
- The middle-aged demographic shows the greatest usage rates.
- Many obtain the medications through private healthcare rather than the NHS.
Finally, clinicians stress that while GLP-1 drugs are potent tools for weight loss, they are not a standalone solution and maintained weight loss hinges on integrated lifestyle support.
